Evidence map›Paper›PMID 41493346›Full record

ArticleFuture science OA2026

"Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?"

Musa Fares Alzahrani, Abdulaziz Albacker, Abdulmajeed Alshabanat, Maram Alharbi, Jawahir Abuhaimed, Nouran Arnous, Yara Alzahrani, Hind Aloraier, Maha Alamri, Rawan Altamimi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Musa Fares AlzahraniDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdulaziz AlbackerDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdulmajeed AlshabanatDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Maram AlharbiOncology Center, Department of Hematology, King Saud University Medical City, Riyadh, Saudi Arabia.
Jawahir AbuhaimedCollege of Medicine, Transfusion Medicine Department, Alfaisal University, Riyadh, Saudi Arabia.
Nouran ArnousDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Yara AlzahraniDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Hind AloraierOncology Center, Department of Hematology, King Saud University Medical City, Riyadh, Saudi Arabia.
Maha AlamriDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Rawan AltamimiMinistry Of Health, Seha Virtual Hospital, Department of Medicine, Riyadh, Saudi Arabia.
Ghazi AlotaibiDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Sarah SewaralthahabDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Fatima AlshaltiOncology Center, Department of Hematology, King Saud University Medical City, Riyadh, Saudi Arabia.
Ibrahim AlrumaihOncology Center, Department of Hematology, King Saud University Medical City, Riyadh, Saudi Arabia.
Ahmad JamalOncology Center, Department of Hematology, King Saud University Medical City, Riyadh, Saudi Arabia.
Farjah AlgahtaniDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Aamer AleemDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsSickle cell disease (SCD) leads to recurrent vaso-occlusive crises (VOC) and hospitalizations, imposing a substantial healthcare burden. Hydroxyurea (HU) is known to reduce VOC frequency and hospitalization rates in SCD; however, data comparing the impact of different HU doses on length of stay (LOS) and clinical outcomes in adults are limited.

methodsThis retrospective study assessed the effect of high- versus low-dose HU on LOS among adults with SCD admitted to medical wards. Secondary endpoints included VOC frequency and hemoglobin electrophoresis findings. Pearson's chi-square and Mann-Whitney tests were used, with significance set at

resultsA total of 141 patients were analyzed (26 on low-dose, 115 on high-dose HU), with a median age of 31 years; 52.5% were female. The overall median LOS was 3 days (IQR 1-10). The low-dose group had a significantly longer median LOS (7 days [IQR 7-9]) compared with the high-dose group (2 days [IQR 2-3];

conclusionHigh-dose HU was linked to shorter hospital stays and favorable hematologic outcomes in adults with SCD.

Indexed as

hydroxyureaSCDsickleSickle cell diseasevaso-occlusive crisis

Identifiers

PMID41493346
PMCPMC12785233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.